This therapy slashes bad cholesterol by nearly 50% without statins or side effects
A new kind of cholesterol treatment is emerging from the lab—and it does not rely on statins. Researchers from the University of Barcelona and the University of Oregon have developed a DNA‑based therapy that switches off a key cholesterol‑controlling gene, cutting “bad” LDL cholesterol by nearly 50% in animal models without the muscle pain and other side effects that drive many patients to abandon traditional drugs. Turning down cholesterol at the gene level At the heart of this breakthrough is PCSK9, a protein that tells the body to remove LDL receptors from the surface of liver cells. When PCSK9 is overactive, fewer receptors are available to clear LDL from the blood, and cholesterol levels climb, increasing the risk of atherosclerosis and heart attack. The new strategy uses tiny DNA molecules called polypurine reverse Hoogsteen hairpins—PPRHs for short—to silence the PCSK9 gene before it can make this protein. Crystal Structure of PCSK9 Source: PDB Two specially designed PPRHs, ...